MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 60.83M +46.7% |
| Revenue (ttm) | n/a |
| Net Income | -25.12M |
| EPS | -0.49 |
| Shares Out | 60.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 362,675 |
| Open | 1.010 |
| Previous Close | 1.010 |
| Day's Range | 1.000 - 1.038 |
| 52-Week Range | 0.870 - 3.190 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | 12.00 (+1,100.0%) |
| Earnings Date | Nov 9, 2026 |
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for MAIA is $12.0, which is an increase of 1,100.00% from the latest price.
News
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, In...
MAIA Biotechnology Quarterly report: Q3 2026
MAIA Biotechnology has published its Q3 2026 quarterly earnings report on November 9, 2026.
MAIA Biotechnology Slides: Corporate presentation
MAIA Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2026.
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
Diamond Equity releases update note on MAIA Biotechnology
Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology (MAIA). The research summary below is from…
MAIA Biotechnology files to sell 751,879 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 751,879 shares of common stock. The company is not selling any…
MAIA Biotechnology Registration statement: Registration filing
MAIA Biotechnology filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biophar...
MAIA Biotechnology reports Phase 3 trial progress in advanced NSCLC
MAIA Biotechnology (MAIA) announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line treatment fo...
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5...
MAIA Biotechnology doses first U.S. patient in THIO-101 trial expansion
MAIA Biotechnology (MAIA) announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-...
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for...
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)...
MAIA Biotechnology files $150M mixed securities shelf
16:17 EDT MAIA Biotechnology (MAIA) files $150M mixed securities shelf
MAIA Biotechnology Registration statement: Registration filing
MAIA Biotechnology filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
MAIA Biotechnology Quarterly report: Q2 2026
MAIA Biotechnology has published its Q2 2026 quarterly earnings report on August 10, 2026.
MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion
MAIA Biotechnology (MAIA) announced initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorp...
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-tre...
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical...
MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial
MAIA Biotechnology (MAIA) announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University, is activated and now enrolling patients. Th...
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWS...
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7...
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotechnology (MAIA) provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line treatment for advanced n...
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer